Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.

Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.

Enhancing childhood obesity management: implementing an obesity registry for Iranian children and adolescents.

Purpose: The rising prevalence of overweight and obesity among children and adolescents is a global public health issue. This trend has led to increased obesity-related comorbidities and a higher risk of adulthood obesity in this sensitive population. This study aims to establish the first obesity registry for Iranian children and adolescents to enhance the understanding of pediatric obesity and its determinants and consequents.

Collateral effects of pandemic control.

The response to COVID-19 altered global dispersal of influenza viruses.

Meal replacements on obesity and leptin: a systematic review and meta-analysis.

The global prevalence of obesity and overweight is a significant concern in the field of public health. Numerous interventional studies have been conducted to assess the possible meal replacements (MRs) effect on anthropometric indicators and indices and laboratory test that reflect obesity. However, there are no comprehensive results in this field.